StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly forteo (teriparatide) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)

QuarterlyAnnual
Latest, Q3 2024
118
Period ended Sep 30, 2024
Change on a year earlier
-19.3%
146 in Q3 2023
History
31 quarters
Since Q1 2017
Sources
27
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedForteo (teriparatide) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
Q3 2024Sep 30, 2024118-19.3%Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 202469.9-52.8%Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 202461.3-49.9%Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023116-27.2%Form 10-K FY2023 (filed 2024-02-21) ↗
Q3 2023Sep 30, 2023146-17.3%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023148+6.9%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023122-11.0%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022160-13.0%Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022177-11.8%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 2022139-36.6%Form 10-Q (filed 2023-08-08) ↗
Q1 2022Mar 31, 2022137-30.8%Form 10-Q (filed 2023-04-27) ↗
Q4 2021Dec 31, 2021184-27.7%Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 2021201-24.7%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 2021218-13.6%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021199-27.1%Form 10-Q (filed 2022-04-29) ↗
Q4 2020Dec 31, 2020254-29.4%Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗

Breakdown

What makes up forteo (teriparatide) — worldwide revenue ($m) [legacy separate disclosure]

Cite this data

StockData. (2026). Eli Lilly Forteo (teriparatide) — Worldwide revenue ($M) [legacy separate disclosure] ($M), quarterly Q1 2017–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_forteo_ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.